will be listed per patient and will document the nature of the 
complaint, seventy, relationship to study drug, course of reaction, 
and action taken. Tabulations will be made of the number of 
patients with complaints, the number of complaints per patient, 
complaint severity and relationship to lymphocyte infusion, and the 
frequency of each type of complaint. All data exclusions, including 
premature terminations, will be recorded and tabulated. 
Abnormalities seen on physical examination will be tabulated. 
Laboratory values will be listed by patient and abnormalities 
flagged. 
The statistical methods used in the analysis of the clinical and 
immunologic safety data include chi-square and the t-test, as 
indicated. 
[310] 
Recombinant DNA Research, Volume 16 
